Literature DB >> 19133978

CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden.

Sylvia Feyler1, Marie von Lilienfeld-Toal, Sarah Jarmin, Lee Marles, Andy Rawstron, A J Ashcroft, Roger G Owen, Peter J Selby, Gordon Cook.   

Abstract

Increased levels of naturally occurring regulatory T cells (T(Reg) cells) have been found in a variety of solid tumours and haematological malignancies. In multiple myeloma (MM), evidence suggests that T(Reg) cells are increased though controversy exists with regards to their function and no relationship to disease stage and treatment has been demonstrated. Here, we demonstrate significantly elevated levels of functional CD4(+)CD25(+)FoxP3(+) T(Reg) cells in a large cohort of patients with MM as well as monoclonal gammopathy of uncertain significance (MGUS) in comparison to age-matched, healthy controls. The frequency of Double Negative T(Reg) cells was also evaluated, demonstrating that these cells were reduced in patients with MM. Furthermore, a characteristic profile of immunomodulatory cytokines in the peripheral blood and bone marrow of patients with MM and MGUS was demonstrated, compared with healthy controls. This data adds further evidence to the understanding of the role of T(Reg) cell subsets in tumour immunology and the fundamentals of the host/tumour immune conflict.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19133978     DOI: 10.1111/j.1365-2141.2008.07530.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  51 in total

1.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

2.  Reconstitution of regulatory T cells after autologous transplantation in multiple myeloma.

Authors:  Prasanth Ganeshan; Ritu Gupta; Mrinali Hakim; Lalit Kumar; Archana Bhaskar; Atul Sharma
Journal:  Int J Hematol       Date:  2011-11-03       Impact factor: 2.490

Review 3.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

4.  The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.

Authors:  Myriam Foglietta; Barbara Castella; Sara Mariani; Marta Coscia; Laura Godio; Riccardo Ferracini; Marina Ruggeri; Vittorio Muccio; Paola Omedé; Antonio Palumbo; Mario Boccadoro; Massimo Massaia
Journal:  Haematologica       Date:  2014-06-27       Impact factor: 9.941

Review 5.  Clinical Development of PD-1 Blockade in Hematologic Malignancies.

Authors:  Matthew J Pianko; Aaron D Goldberg; Alexander M Lesokhin
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

Review 6.  Immunotherapeutic approaches to treat multiple myeloma.

Authors:  Mieke W H Roeven; Willemijn Hobo; Nicolaas Schaap; Harry Dolstra
Journal:  Hum Vaccin Immunother       Date:  2013-12-11       Impact factor: 3.452

7.  The immune microenvironment of myeloma.

Authors:  Kimberly Noonan; Ivan Borrello
Journal:  Cancer Microenviron       Date:  2011-08-25

8.  Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Authors:  Yawara Kawano; Oksana Zavidij; Jihye Park; Michele Moschetta; Katsutoshi Kokubun; Tarek H Mouhieddine; Salomon Manier; Yuji Mishima; Naoka Murakami; Mark Bustoros; Romanos Sklavenitis Pistofidis; Mairead Reidy; Yu J Shen; Mahshid Rahmat; Pavlo Lukyanchykov; Esilida Sula Karreci; Shokichi Tsukamoto; Jiantao Shi; Satoshi Takagi; Daisy Huynh; Antonio Sacco; Yu-Tzu Tai; Marta Chesi; P Leif Bergsagel; Aldo M Roccaro; Jamil Azzi; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 9.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

10.  Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function.

Authors:  Maciej Kmieciak; Madhu Gowda; Laura Graham; Kamar Godder; Harry D Bear; Francesco M Marincola; Masoud H Manjili
Journal:  J Transl Med       Date:  2009-10-22       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.